A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile
- PMID: 10566641
- DOI: 10.1210/jcem.84.11.6148
A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile
Abstract
Polycystic ovary syndrome (PCOS) is characterized by hyperandrogenism, chronic anovulation, and oligomenorrhea (O/M). PCOS has variable clinical phenotypes, biochemical features, and metabolic abnormalities. To determine the prevalence of PCOS in the Greek population as well as the metabolic parameters, we performed a cross-sectional study of 192 women of reproductive age (17-45 yr), living on the Greek island of Lesbos. They were divided into 4 groups according to the presence of hirsutism (defined as a Ferriman-Gallwey score > or = 6) and O/M: group N (n = 108), regular menses and absence of hirsutism; group 1 (n = 56), regular menses and hirsutism; group 2 (n = 10), O/M and absence of hirsutism; and group 3 (n = 18), O/M and hirsutism. Body mass index, waist to hip ratio, and mean blood pressure did not differ among the studied groups. Hormonal profile was assessed by measuring free testosterone (FT). The prevalence of PCOS, defined by the presence of O/M and biochemical hyperandrogenism (FT > or = 95th percentile of the normal women), was estimated to be 6.77% (13 women of 192). Higher FT levels were observed in group 3 (O/M and hirsutism) compared with groups N (P < 0.00001) and 1 (P < 0.0001) and in groups 1 (hirsutism) and 2 (O/M) compared with group N (P < 0.0001 and P < 0.005, respectively). Sex hormone-binding globulin levels were lower in women with PCOS and in groups 1 and 3 than those in group N (P < 0.002, P < 0.02, and P < 0.002, respectively) independently of the body mass index. The metabolic profile was investigated by measurements of fasting glucose (FG), fasting insulin (FI), and estimation of the fasting glucose to insulin ratio (FG:I ratio). After covariance adjusted for the BMI, FI levels were higher in group 3 and in women with PCOS than in the normal (P < 0.005 and P < 0.002, respectively) and the hirsute (P < 0.05 and P < 0.02, respectively) women, whereas FG levels did not differ among the studied groups. The FG:I ratio was lower in group 3, group 1, and in women with PCOS than in normal women (P < 0.05). Finally, a high incidence of family history of diabetes mellitus (P = 0.001) and menstrual disorders (P = 0.01) was observed in women with PCOS, in contrast to the normal and hirsute women. In conclusion, PCOS appears to be a particularly common endocrine disorder in the Greek population under study (prevalence, 6.77%); furthermore, it is associated with certain metabolic abnormalities. These data also suggest that the severity of the fasting hyperinsulinemia is associated with the severity of the clinical phenotype of hyperandrogenism independently of obesity.
Similar articles
-
[Exploration of the classification of polycystic ovarian syndrome].Zhonghua Fu Chan Ke Za Zhi. 2006 Oct;41(10):684-8. Zhonghua Fu Chan Ke Za Zhi. 2006. PMID: 17199924 Chinese.
-
Comparison of clinical and laboratory characteristics of cases with polycystic ovarian syndrome based on Rotterdam's criteria and women whose only clinical signs are oligo/anovulation or hirsutism.Arch Gynecol Obstet. 2006 Jul;274(4):227-32. doi: 10.1007/s00404-006-0173-8. Epub 2006 May 12. Arch Gynecol Obstet. 2006. PMID: 16691383
-
Glucose intolerance, insulin resistance, and hyperandrogenemia in first degree relatives of women with polycystic ovary syndrome.J Clin Endocrinol Metab. 2003 May;88(5):2031-6. doi: 10.1210/jc.2002-021499. J Clin Endocrinol Metab. 2003. PMID: 12727950
-
Association between biochemical hyperandrogenism parameters and Ferriman-Gallwey score in patients with polycystic ovary syndrome: A systematic review and meta-regression analysis.Clin Endocrinol (Oxf). 2017 Sep;87(3):217-230. doi: 10.1111/cen.13389. Epub 2017 Jun 30. Clin Endocrinol (Oxf). 2017. PMID: 28575537 Review.
-
Polycystic Ovary Syndrome.Obstet Gynecol. 2018 Aug;132(2):321-336. doi: 10.1097/AOG.0000000000002698. Obstet Gynecol. 2018. PMID: 29995717 Review.
Cited by
-
Predictors of subclinical cardiovascular disease in women with polycystic ovary syndrome: interrelationship of dyslipidemia and arterial blood pressure.Int J Endocrinol. 2015;2015:812610. doi: 10.1155/2015/812610. Epub 2015 Mar 24. Int J Endocrinol. 2015. PMID: 25878664 Free PMC article.
-
Metabolic and endocrine effects of bisphenol A exposure in market seller women with polycystic ovary syndrome.Environ Sci Pollut Res Int. 2016 Dec;23(23):23546-23550. doi: 10.1007/s11356-016-7573-5. Epub 2016 Sep 10. Environ Sci Pollut Res Int. 2016. PMID: 27614642
-
Polycystic ovary syndrome in adolescents: current and future treatment options.Paediatr Drugs. 2006;8(5):311-8. doi: 10.2165/00148581-200608050-00004. Paediatr Drugs. 2006. PMID: 17037948 Review.
-
Efficacy, Feasibility and Acceptability of a Mediterranean Diet Intervention on Hormonal, Metabolic and Anthropometric Measures in Overweight and Obese Women with Polycystic Ovary Syndrome: Study Protocol.Metabolites. 2022 Mar 31;12(4):311. doi: 10.3390/metabo12040311. Metabolites. 2022. PMID: 35448498 Free PMC article.
-
Minimal difference in phenotype between adolescents and young adults with polycystic ovary syndrome.Fertil Steril. 2019 Feb;111(2):389-396. doi: 10.1016/j.fertnstert.2018.10.020. Epub 2018 Dec 7. Fertil Steril. 2019. PMID: 30527835 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical